Assessing the Optimal Position for Vedolizumab in the Treatment of Ulcerative Colitis: A Simulation Model.
| Author | |
|---|---|
| Abstract |
:
Vedolizumab, an α4β7 integrin monoclonal antibody inhibiting gut lymphocyte trafficking, is an effective treatment for ulcerative colitis (UC). We evaluated the optimal position of vedolizumab in the UC treatment paradigm. |
| Year of Publication |
:
2018
|
| Journal |
:
Inflammatory bowel diseases
|
| Volume |
:
24
|
| Issue |
:
2
|
| Number of Pages |
:
286-295
|
| Date Published |
:
2018
|
| ISSN Number |
:
1078-0998
|
| URL |
:
https://academic.oup.com/ibdjournal/article-lookup/doi/10.1093/ibd/izx045
|
| DOI |
:
10.1093/ibd/izx045
|
| Short Title |
:
Inflamm Bowel Dis
|
| Download citation |
